Floatz logo

Inno-206

Refractory Primary Peritoneal Endometrioid Adenocarcinoma

National Cancer Institute (NCI)Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Refractory Primary Peritoneal Endometrioid Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Olaparib
National Cancer Institute (NCI)
Phase 2CCC
Durvalumab
National Cancer Institute (NCI)
Phase 2CCC
Hycamtin
National Cancer Institute (NCI)
Phase 2CCC
Cediranib
National Cancer Institute (NCI)
Phase 2CCC

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →